Indisulam
10mM in DMSO
- Product Code: 199092
CAS:
165668-41-7
| Molecular Weight: | 385.85 g./mol | Molecular Formula: | C₁₄H₁₂ClN₃O₄S₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Indisulam is primarily investigated for its antitumor activity, particularly in the treatment of various cancers. It functions as a sulfonamide-based anticancer agent that modulates cell cycle progression by inducing G1 arrest in tumor cells. Its mechanism involves binding to the protein RBM39 through recruitment to the CUL4–DCAF15 E3 ubiquitin ligase complex, leading to targeted degradation of RBM39, which disrupts RNA splicing in cancer cells. This selective splicing modulation is especially effective in hematologic malignancies and certain solid tumors.
It has shown promising results in preclinical and clinical studies for cancers such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and non-small cell lung cancer (NSCLC). Indisulam’s efficacy appears to be higher in tumors expressing high levels of DCAF15, making it a candidate for precision oncology approaches. Ongoing research focuses on identifying biomarkers to predict response and improving its therapeutic window through combination regimens with other anticancer agents.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿1,850.00 |
+
-
|
Indisulam
Indisulam is primarily investigated for its antitumor activity, particularly in the treatment of various cancers. It functions as a sulfonamide-based anticancer agent that modulates cell cycle progression by inducing G1 arrest in tumor cells. Its mechanism involves binding to the protein RBM39 through recruitment to the CUL4–DCAF15 E3 ubiquitin ligase complex, leading to targeted degradation of RBM39, which disrupts RNA splicing in cancer cells. This selective splicing modulation is especially effective in hematologic malignancies and certain solid tumors.
It has shown promising results in preclinical and clinical studies for cancers such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and non-small cell lung cancer (NSCLC). Indisulam’s efficacy appears to be higher in tumors expressing high levels of DCAF15, making it a candidate for precision oncology approaches. Ongoing research focuses on identifying biomarkers to predict response and improving its therapeutic window through combination regimens with other anticancer agents.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :